Trianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.
Two research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners.
https://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.png00entherahttps://www.entherapharmaceuticals.com/wp-content/uploads/2019/10/logo-300x85.pngenthera2016-11-23 09:10:362020-07-28 11:25:19BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer
Enthera and Trianni Announce Licensing Agreement
/in Press ReleasesTrianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.
BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer
/in Press ReleasesTwo research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners.